Goserelin
About
Therapy type: Hormone therapy
Therapy strategy: Gonadotropin-releasing hormone (GnRH) agonist
Mappings
NCI Thesaurus: Goserelin (coding:ncit:C1374)
RxNorm: goserelin (coding:rxcui:50610, coding:omop:1366310)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| EMA (1) FDA (2) | ER positive, HER2-negative | Invasive Breast Carcinoma | Anastrozole, Goserelin, Ribociclib | |
| EMA (1) FDA (2) | HER2-negative, PR positive | Invasive Breast Carcinoma | Anastrozole, Goserelin, Ribociclib | |
| EMA (1) FDA (2) | ER positive, HER2-negative, PR positive | Invasive Breast Carcinoma | Anastrozole, Goserelin, Ribociclib | |
| EMA (1) FDA (2) | ER positive, HER2-negative | Invasive Breast Carcinoma | Goserelin, Letrozole, Ribociclib | |
| EMA (1) FDA (2) | HER2-negative, PR positive | Invasive Breast Carcinoma | Goserelin, Letrozole, Ribociclib | |
| EMA (1) FDA (2) | ER positive, HER2-negative, PR positive | Invasive Breast Carcinoma | Goserelin, Letrozole, Ribociclib |